{
  "ticker": "MRNA",
  "company_name": "Moderna, Inc.",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT05668741",
      "title": "A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)",
      "status": "RECRUITING",
      "phase": "PHASE1, PHASE2",
      "condition": "Cystic Fibrosis",
      "start_date": "2023-02-27",
      "completion_date": "2027-05-12",
      "enrollment": 0,
      "sponsor": "Vertex Pharmaceuticals Incorporated"
    }
  ],
  "summary": {
    "total_trials": 1,
    "by_phase": {
      "PHASE1, PHASE2": 1
    },
    "by_status": {
      "RECRUITING": 1
    },
    "active_trials": 1,
    "completed_trials": 0,
    "conditions": [
      "Cystic Fibrosis"
    ],
    "lead_stage": "unknown"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-12T09:43:05.460244",
    "search_query": "Moderna, Inc.",
    "url": "https://clinicaltrials.gov/search?term=Moderna,+Inc."
  }
}